NO820319L - Antimykotisk middel i form av stifter og med hoey virksom stoff frigjoering - Google Patents
Antimykotisk middel i form av stifter og med hoey virksom stoff frigjoeringInfo
- Publication number
- NO820319L NO820319L NO820319A NO820319A NO820319L NO 820319 L NO820319 L NO 820319L NO 820319 A NO820319 A NO 820319A NO 820319 A NO820319 A NO 820319A NO 820319 L NO820319 L NO 820319L
- Authority
- NO
- Norway
- Prior art keywords
- antimycotic agents
- contain
- agents according
- active substance
- acid
- Prior art date
Links
- 239000003429 antifungal agent Substances 0.000 title claims 7
- 239000000126 substance Substances 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 238000009472 formulation Methods 0.000 claims abstract description 16
- 150000007980 azole derivatives Chemical class 0.000 claims abstract description 6
- 239000013543 active substance Substances 0.000 claims description 16
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002270 dispersing agent Substances 0.000 claims description 7
- 230000000843 anti-fungal effect Effects 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 4
- OWEGWHBOCFMBLP-UHFFFAOYSA-N 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one Chemical compound C1=CN=CN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 OWEGWHBOCFMBLP-UHFFFAOYSA-N 0.000 claims 1
- DALSNPRWUFOYDT-UHFFFAOYSA-N 1-[(2-chlorophenyl)-(4-phenylphenyl)methyl]imidazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)C1=CC=C(C=2C=CC=CC=2)C=C1 DALSNPRWUFOYDT-UHFFFAOYSA-N 0.000 claims 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002206 bifonazole Drugs 0.000 claims 1
- 229960003344 climbazole Drugs 0.000 claims 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims 1
- 229960004022 clotrimazole Drugs 0.000 claims 1
- 229950000194 lombazole Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 230000001857 anti-mycotic effect Effects 0.000 abstract description 3
- 239000002543 antimycotic Substances 0.000 abstract description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract description 2
- 238000003892 spreading Methods 0.000 abstract description 2
- 239000000194 fatty acid Substances 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- -1 Fatty acid esters Chemical class 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 150000002191 fatty alcohols Chemical class 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical class CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010012504 Dermatophytosis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241001460074 Microsporum distortum Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical class CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 229940089456 isopropyl stearate Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XUJLWPFSUCHPQL-UHFFFAOYSA-N 11-methyldodecan-1-ol Chemical compound CC(C)CCCCCCCCCCO XUJLWPFSUCHPQL-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- LZILFXHGPBJADI-UHFFFAOYSA-N 2-(2-hydroxypropoxy)propan-1-ol;nonanoic acid Chemical compound CC(O)COC(C)CO.CCCCCCCCC(O)=O LZILFXHGPBJADI-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000207740 Lemna minor Species 0.000 description 1
- 235000006439 Lemna minor Nutrition 0.000 description 1
- QZXSMBBFBXPQHI-UHFFFAOYSA-N N-(dodecanoyl)ethanolamine Chemical compound CCCCCCCCCCCC(=O)NCCO QZXSMBBFBXPQHI-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- UFIYKNIUNRVRSI-UHFFFAOYSA-N hexadecyl octadecyl sulfate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCCOS(=O)(=O)OCCCCCCCCCCCCCCCC UFIYKNIUNRVRSI-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/05—Stick
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cephalosporin Compounds (AREA)
Description
Oppfinnelsen vedrører nye formuleringer av de kjente antimykotiske azolderivater som har en høyere frigjøring av de virksomme stoffer og derved muliggjør en korttids-terapi.
For behandling av mykoser hos mennesker, fremfor alt hud-mykoser og mykoser av hydvedhengstrukturer er det allerede blitt kjent tilberedninger av antimykotiske derivater. Med disse tilberedninger kreves for en fullstendig sanering
14 til 21 dagers terapitid.
For å komme til en forkortelse av terapivarigheten krever man spesielt til eliminering av kimene respektiv å oppnå dermed en mykologisk sikkerhets sanering en høyere frigjøring av
de virksomme stoffer i vandig miljø. Dertil er de kjente formuleringer bare begrenset egnet,fordi av det tilstede-værende virksomme stofftilbud oppløser seg bare en liten del
i væskevolum - altså på infeksjonsstedet- Hvis man uten ytterligere økning av den virksomme stoffkonsentrasjon vil oppnå en forkortning av terapivarigheten, f.eks. til en dag ved engangs-applikasjon, må man sørge for en optimal fri-gjøring av det virksomme stoff.
Det er nu funnet at stift-formuleringer av antimykotiske-axolderivater, som ved siden av vanlige stift-formulerings-hjelpestoffer inneholder 3-5% benzylalkohol og 2,5-10% spredemiddel, frigjør det virksomme stoff i høyere grad og derved muliggjør en forkortning av terapivarigheten til en dag. Denne effekt med høyere virksom stoff-frigjøring kan oppnås inntil en tier-potens.
Virksomme stoffer som kan formuleres på denne måte er alle antimykotisk virksomme derivater, spesielt imidazbl- og triazolderivater. De er til stede i midlene ifølge oppfinnelsen i mengder på 0,05-1%, fortrinnsvis på 0,1-1%.
Eksempelvis skal det nevnes forbindelsene med følgende formler:
Tallrike ytterligere antimykotiske virksomme azolderivater er kjent fra De-OS 2'430 039- De kan likeledes tjene som virksomme stoffer i midlene ifølge oppfinnelsen.
Med spredemidler forstås oljeaktige væsker som fordeler seg
spesielt godt på huden (R. Keymer, Pharm. Ind. 3<_>21970,
577-581). For midlene ifølge oppfinnelsen egner det seg som spredemidler spesielt følgende forbindelser:
Silikonoljer av forskjellig virkositet.
Fettsyreestere som etylstearatæ di-n-butyl-adipat, laurinsyre-heksylester, dipropylen-glykolpelargonat, estere av en for-grenet fettsyre av midlere kjedelengde med mettede fettalkoholer ci£~ c±q' isopropylmyristat, isopropylpalmitat, kapryl/ kaprinsyreestere av mettede fettalkoholer av kjedelengder C^g. isopropylstearat, oljesyreoleyester, oljesyre decylestere, etyloleat, melkesyreetylester, voksaktige fettsyreestere som kunstige andegump-kjertelfett, dibutylftalat, adipinsyre-diisopropylester, sistnevnte beslektede esterblandinger, myristyllactat, cetyllactat, 2åetylheksylpalmitat, myristyl-myristat og lignende.
Triglysirider som capryl/caprinsyretriglyserid, triglyserid-blandinger med plantefettsyrer av kjedelengder cg-ci2eHer andre spesielt valgte naturlige fettsyrer, partialglyseridbland-inger av mettede eller umettede, eventuelt også hydroksyl-gruppeholdige fettsyrer, monoglyserider av Cg/C-^-f ettsyrer og lignende.
Fettalkoholer som isotridecylalkohol, 2åoktyldodecanol, cetyl-stearyl-alkohol, oleylalkohol.
Fettsyrer som f.eks. oljesyre.
Spesielt godt egnede spredende oljer er følgende: Isopropylmyristat, isopropylpalmitat, capryl/caprinsyreestere av mettede fettalkoholer av kjedelengder C,~-C,0, voksaktige
L2. lo
fettsyreestere som kunstif andegump-kjertelfett, silikon-
ol j e , isopropylmyristat/isopropylstearat/isopropylpalmitat-blanding.
Følgende ytterligere hjelpe-* og/eller formuleringsgunnhjelpe-stoffer kan anvendes ved fremstilling av midlene ifølge oppfinnelsen: Ikke-ionogene emulgatorer fremstilt ved om-setning av høyere mettede fettalkoholer med etylenoksyd. Natriumstearat, cetylstearylalkohol, stearinsyre, 2-oktyl-dodecanol (Guerbet-alkohol), "glyserylstearater", blanding av fettalkoholer, voks og oljer, blanding av mono- og diglyserider av palmitin- og stearingsyre, kokosfettsyre-monoetanolamid, kolloiddispers blanding av cetyl-stearyl-alkohol og natrium-cetyl-stearylsulfat, oljesyredecylester, n-heksadecanol, laurinsyremonoetanolamid, cetylpalmitat, svakt nettdannet polyacrylsyre av ekstremt høy molekylvekt.
Glyserol, parafin tyktflytende, parafin tyntflytende, tri-etanolamin, collagen, allantoin. novantisolsyre, parfymeolje, natriumhydroksyd, propylenglykol, di- og tripropylenglykol, vokser etc.
Videre er det egnet:
a. stoff som f.eks. kan stabilisere en suspensjon, f.eks,
kolloidal kiselsyre, montmorillonit og lignende.
b. Tensider (omfattende emulgatorer og fuktemiddel), f.eks.
1. anione-aktive som Na-laurylsulfat, fettalkoholeter-sulfater, mono/dialkylpolyglykoleterortofosforsyreester-monoetanolaminsalt; 2. kation-aktive som cetyltrimetylammoniumklorid; 3. amfolyttiske som di-Na-N-lauryl-$-ininodipropionat eller lecitin; 4. ikke-ionogene, f.eks. polyoksyetylert rizinusolje, polyoksyetylert sorbitab-monooleat, sorbitan-monostearat, cetylalkohol, glyserolmonostearat, polyoksyetylen-stearat, alkylfenolpolyglykoleter,
c. Stabilisatorer for å hindre den ved enkelte virksomme stoffer inntredende kjemiske avbygning som antioksydanter f.eks. tocoferoler, butylhydroksyanisol.
Som geldannere kommer det på tale slike makromolykylare forbindelser som kan oppløse seg respektiv svelle såvel i vann som også i organiske oppløsningsmidler og etter tørkning danner en type film.
Følger man en inndeling av de makromolekylære hjelpestoffer (Keipert et al., Die Pharmazie 28. 1973, 145-183) så kommer
det fremfor alt til anvendelse ioniske makromylekyler i deres saltform. Disse er bl.a. natriumkarboksymetylcellulose, polyacrylsyre, polymetacrylsyre og deres salter, natriumamylo-pektinsemiglykolat, alginsyre og propylenglykol-alginat som natriumsalt, arabisk gummi, xantan-gummi, guar-gummi.
amfotære makromolekyler som protein-derivater, f.eks. gela-tiner er likeledes egnet som ikke-ioniske polymere, fveks. metylcellulose, hydroksypropylcellulose og oppløselig stiv-elser som oppfyller overnevnte krav.
Som oppløsningsmidler er det egnet vann og også alle med vann blandbare oppløsningsmidler. I betraktning kommer f.eks. alkan-oler som etanol og iropropylalkohol, propylenglykol, metylcello-solv, cellosolv, estere, morfoliner, dioksan, dimetylsulfoksyd, dimetylformamid, tetrahydrofuran, cykloheksanon.
Det kan ved fremstillingen av formuleringen ifølge oppfinnelsen anvendes et eller flere oppløsningsmidler.
Fremstilling av stiftene.
De enkelte komponenter smeltes respektiv oppløses ved 70°C - 75°C. Ferdigblandingen utluftes, idet man lar massen stå i oppløst tilstand et kvarter. Det bør unngås å oppvarme smeiten for langt og høyere enn nødvendig. Utstøpning av stifene foregår ved ca. 70°C. Det bør ikke danne seg noen luftinneslutninger. Ved flammebehandling av stiftene oppnås en glinsende overflate.
Sammeligningseksempel A: Stift som inneholder hverken benzylalkohol eller spredemiddel.
Sammenligningseksempel B: Stift som inneholder benzylalkohol, imidlertid intet spredemiddel. Eksempel 1;
Eksempel 2:
Eksempel 3:
Eksempel 4:
Eksempel 5:
Eksempel 6:
Virksomhetsprøve av midlene ifølge oppfinnelsen på trikofyton- infisert marsvin.
Som prøvemodell til sammenlignende virksomhetsprøving av formuleringen ifølge oppfinnelsen ble det anvendt trikofyton-infiserte Pirbirgth-white-marsvin med en gjennomsnitt-lig vekt på 600 g. Dyrene ble barbert på ryggen med en elektrisk maskin således at det ble bibeholdt ca. 1/10 mm lange hårstumper.
Infeksjonen med trikofyton metagrofytes foregikk ved lett utrivning av en 24 timer i Sabouraud-næringsoppløsning virket sporesuspensjon av frembringeren på en ca. 2 x 2 cm stor flate av den barberte rygg på dyret. Det ble påført
5
pr. dyr 0,5 ml kimsuspensjon som inneholdt 1 - 3 x 10 infektiøse soppartikler.
Ved denne infeksjonsmodus viser det seg 2-3 dager post infectionem de første symtomer av dermatofytose som rødning og skorpedannelse av huden. Ved ubehandlede dyr er ca. 14 dager p.i. dermatofytosen maksimalt utpreget: flekkaktig hår-avfall og blodige integumentdefekter innen en betent endret skorpet kantsone.
Formuleringene som skulle undersøkes ble applisert en gang på annen dag post infectionem lokalt på de røde infeksjons-steder på dyret og utrevet lett med en hornspatel. Det ble hver gang påført 0,5 ml av formuleringen = 5 mg virksomt stoff ( l%ig formulering). Vurderingen av infeksjonsfor-løpet foregikk daglig' inntil 20 dag ' p . i .
Prøveresultatene fremgår av følgende tabell.
Anvender man istedenfor formuleringen ifølge oppfinnelsen slike som ikke inneholder benzylalkohol og ikke spredemiddel (sammenligningseksempel A og B) så oppnås en effekt som tilsvarer effekten'ved formuleringen ifølge oppfinnelsen først etter tre gangers applikasjon.
Claims (6)
1. Antimykotiske midler med høy frigjøring av de virksomme stoffer inneholdende azolderivater og vanlige formulerings-hjelpestoffer, karakterisert ved at de foreligger i stiftform og inneholder 3-5% benzylalkohol og 2,5-10% spredemiddel.
2. Antimykotiske midler ifølge krav 1, karakterisert ved at de som virksomt stoff inneholder clotrimazol med formel
3. Antimykotiske midler ifølge krav 1, karakterisert ved at de som virksomt stoff inneholder trifonazol med formel
4. Antimykotiske midler ifølge krav 1, karakterisert ved at de som virksomt stoff inneholder climbazol med formel
5. Antimykotiske midler ifølge krav 1, karakterisert ved at de som virksomt stoff inneholder lombazol med formel
6. Antimykotiske midler ifølge krav 1, karakterisert ved at de inneholder de antimykotiske azolderivater i mengder på 0,05-1%, fortrinnsvis 0,1-1%.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19813106635 DE3106635A1 (de) | 1981-02-23 | 1981-02-23 | Antimykotisches mittel mit hoher wirkstoff-freisetzung in form von stiften |
Publications (1)
Publication Number | Publication Date |
---|---|
NO820319L true NO820319L (no) | 1982-08-24 |
Family
ID=6125514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO820319A NO820319L (no) | 1981-02-23 | 1982-02-03 | Antimykotisk middel i form av stifter og med hoey virksom stoff frigjoering |
Country Status (14)
Country | Link |
---|---|
US (1) | US4457938A (no) |
EP (1) | EP0058887B1 (no) |
JP (1) | JPS57156413A (no) |
AT (1) | ATE6988T1 (no) |
AU (1) | AU8032682A (no) |
CA (1) | CA1169770A (no) |
DE (2) | DE3106635A1 (no) |
DK (1) | DK76582A (no) |
ES (1) | ES509798A0 (no) |
FI (1) | FI820563L (no) |
IL (1) | IL65057A (no) |
NO (1) | NO820319L (no) |
PH (1) | PH18258A (no) |
ZA (1) | ZA821137B (no) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3204124A1 (de) * | 1982-02-06 | 1983-08-18 | Bayer Ag, 5090 Leverkusen | Antimykotische tampons mit hoher wirkstoff-freisetzung |
DE3243546A1 (de) * | 1982-11-25 | 1984-05-30 | Bayer Ag, 5090 Leverkusen | Antimykotische mittel in gelform zur behandlung von pilzinfektionen der mundhoehle |
DE3244027A1 (de) * | 1982-11-27 | 1984-05-30 | Bayer Ag, 5090 Leverkusen | Antimykotische mittel mit hoher wirkstoff-freisetzung in form von gelsystemen |
DE3311701A1 (de) * | 1983-03-30 | 1984-10-04 | Bayer Ag | Antimykotische mittel mit hoher wirkstoff-freisetzung in form von creme |
DE3311700A1 (de) * | 1983-03-30 | 1984-10-04 | Bayer Ag | Antimykotische mittel mit hoher wirkstoff-freisetzung in form von loesung und spray |
DE3339236A1 (de) * | 1983-10-28 | 1985-05-09 | Bayer Ag | Arzneimittelzubereitung |
US4678663A (en) * | 1984-02-06 | 1987-07-07 | Nuetrogena Corporation | Hydroquinone composition having enhanced bio-availability and percutaneous adsorption |
US4636520A (en) * | 1984-07-16 | 1987-01-13 | Fujisawa Pharmaceutical Co., Ltd. | Antifungal composition employing pyrrolnitrin in combination with an imidazole compound |
DE3520098A1 (de) * | 1985-06-05 | 1986-12-11 | Bayer Ag, 5090 Leverkusen | Azolderivate enthaltende formulierungen sowie ihre verwendung zur atraumatischen nagelentfernung |
US5110809A (en) * | 1988-03-21 | 1992-05-05 | Bristol-Myers Squibb Company | Antifungal gel formulations |
US4867971A (en) * | 1988-04-22 | 1989-09-19 | Colgate-Palmolive Company | Low pH shampoo containing climbazole |
US5087620A (en) * | 1990-05-17 | 1992-02-11 | Bristol-Myers Squibb Co. | Controlled dermal penetration enhancement using imidazoles |
JP2555555B2 (ja) * | 1991-07-03 | 1996-11-20 | 武田薬品工業株式会社 | 抗真菌性外用製剤 |
US5711954A (en) * | 1992-06-08 | 1998-01-27 | Schering-Plough Healthcare Products, Inc. | Stable imidazole anti-fungal powder compositions |
US5284649A (en) * | 1992-09-29 | 1994-02-08 | The Procter & Gamble Company | Deodorant gel sticks containing 1-hydroxy pyridinethione active |
EP2007390A4 (en) * | 2006-04-04 | 2009-11-25 | Avner Shemer | TREATMENT KIT FOR SKIN INFECTION |
US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
MX363386B (es) | 2013-10-03 | 2019-03-20 | Dow Pharmaceutical Sciences | Formulaciones de efinaconazol estabilizadas. |
CN105848719A (zh) | 2013-11-22 | 2016-08-10 | 道尔医药科学公司 | 抗感染的方法、组合物和装置 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2799613A (en) * | 1954-09-09 | 1957-07-16 | Merck Ag E | Fungicides and bactericides and process of applying |
US3502594A (en) * | 1965-12-28 | 1970-03-24 | Gerhard W Ahrens | Synergistic antioxidant composition for natural oleaginous materials |
US3483008A (en) * | 1966-08-01 | 1969-12-09 | Daniel A Naeve | Method of preparing a water-soluble protein lotion |
US3903287A (en) * | 1971-02-05 | 1975-09-02 | Bayer Ag | Imidazolyl ketones for treating mycotic infections |
GB1327853A (en) * | 1971-05-24 | 1973-08-22 | Ici Ltd | Griseofulvin compositions |
US3856931A (en) * | 1972-08-01 | 1974-12-24 | Schering Ag | Medicated stick |
DE2430039C2 (de) * | 1974-06-22 | 1983-11-10 | Bayer Ag, 5090 Leverkusen | Climbazol in kosmetischen Mitteln |
DE2461406C2 (de) * | 1974-12-24 | 1984-06-14 | Bayer Ag, 5090 Leverkusen | Azolyl-(1)-methane und deren Salze, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
DE2851116A1 (de) * | 1978-11-25 | 1980-06-12 | Bayer Ag | Hydroxyethyl-azole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
US4268498A (en) * | 1979-07-16 | 1981-05-19 | Revlon, Inc. | Clear cosmetic sticks |
-
1981
- 1981-02-23 DE DE19813106635 patent/DE3106635A1/de not_active Withdrawn
-
1982
- 1982-02-03 NO NO820319A patent/NO820319L/no unknown
- 1982-02-05 US US06/346,479 patent/US4457938A/en not_active Expired - Fee Related
- 1982-02-10 AU AU80326/82A patent/AU8032682A/en not_active Abandoned
- 1982-02-11 AT AT82101001T patent/ATE6988T1/de not_active IP Right Cessation
- 1982-02-11 DE DE8282101001T patent/DE3260099D1/de not_active Expired
- 1982-02-11 EP EP82101001A patent/EP0058887B1/de not_active Expired
- 1982-02-19 FI FI820563A patent/FI820563L/fi not_active Application Discontinuation
- 1982-02-19 IL IL65057A patent/IL65057A/xx unknown
- 1982-02-22 PH PH26895A patent/PH18258A/en unknown
- 1982-02-22 CA CA000396788A patent/CA1169770A/en not_active Expired
- 1982-02-22 ZA ZA821137A patent/ZA821137B/xx unknown
- 1982-02-22 DK DK76582A patent/DK76582A/da not_active Application Discontinuation
- 1982-02-22 JP JP57026173A patent/JPS57156413A/ja active Pending
- 1982-02-22 ES ES509798A patent/ES509798A0/es active Granted
Also Published As
Publication number | Publication date |
---|---|
EP0058887A1 (de) | 1982-09-01 |
DE3260099D1 (en) | 1984-05-17 |
ES8303092A1 (es) | 1983-02-01 |
DE3106635A1 (de) | 1982-09-09 |
DK76582A (da) | 1982-08-24 |
EP0058887B1 (de) | 1984-04-11 |
US4457938A (en) | 1984-07-03 |
IL65057A0 (en) | 1982-04-30 |
FI820563L (fi) | 1982-08-24 |
ATE6988T1 (de) | 1984-04-15 |
PH18258A (en) | 1985-05-13 |
IL65057A (en) | 1985-06-30 |
CA1169770A (en) | 1984-06-26 |
ES509798A0 (es) | 1983-02-01 |
AU8032682A (en) | 1982-09-02 |
ZA821137B (en) | 1983-01-26 |
JPS57156413A (en) | 1982-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO820319L (no) | Antimykotisk middel i form av stifter og med hoey virksom stoff frigjoering | |
NO158922B (no) | Fremgangsmaate til fremstilling av azolderivatholdig antimykotisk middel med hoey frigjoering av virksomme stoffer. | |
NO813932L (no) | Antimykotisk middel med hoey virksom stoff-frigjoering i form av elastiske flytende plastere | |
SE455835B (sv) | Topiskt anbringbar farmaceutisk beredning pa basis av en olje/vattenemulsion samt forfarande for framstellning derav | |
JPS6322015A (ja) | 局所適用のための医薬製剤 | |
US6017909A (en) | Salts of azelastine having improved solubility effective at treating psoriasis and providing a cytoprotective effect | |
JPH0466844B2 (no) | ||
CA1175354A (en) | Antimycotic agents which have a good release of active compound and are in the form of elastic liquid plasters | |
CN111050767A (zh) | 预防或治疗睡眠障碍的组合物 | |
AU747088B2 (en) | Use of rhamnolipids in wound healing, treating burn shock, atherosclerosis, organ transplants, depression, schizophrenia and cosmetics | |
JP2010184903A (ja) | 外用医薬組成物 | |
JPH1129460A (ja) | 敏感肌用の化粧料 | |
EP1363626A1 (en) | Antifungal remedy formulation for external application | |
JP2991680B2 (ja) | 新規な抗フリーラジカルメラトニン誘導体、及びこれを含有する組成物 | |
NO834083L (no) | Antimykotisk middel med hoey virksom stoffrigjoering i form av gelsystemer | |
JPH06239757A (ja) | 抗アレルギー剤 | |
DE3311700A1 (de) | Antimykotische mittel mit hoher wirkstoff-freisetzung in form von loesung und spray | |
EP0128459A2 (de) | Antimykotische Mittel für einmalige gynäkologische Behandlung | |
AT380166B (de) | Verfahren zur herstellung topisch applizierbarer pharmazeutischer praeparate, enthaltend salze von alkancarbonsaeuren | |
DE2004610A1 (de) | Toilettenpräparationen | |
JPH09309827A (ja) | 抗真菌外用剤 | |
DE3243544A1 (de) | Antimykotische mittel fuer einmalige gynaekologische behandlung | |
CN113712900A (zh) | 一种枸橼酸托法替布软膏组合物及其制备方法 | |
DE3311701A1 (de) | Antimykotische mittel mit hoher wirkstoff-freisetzung in form von creme | |
JPH07238021A (ja) | 皮膚刺激作用のない製薬用軟膏及びその製造方法 |